In the in vitro assessments, FH-EB02, which has a weaker anti-EGFR and a more potent anti-B7H3 arm (Fig. 2B, G, H), demonstrated a greater binding capacity with tumor cells (Fig. 3A), higher selectivity for B7H3/EGFR coexpressing tumor cells (Fig. 3G), as well as prominent ADCC effect (Fig. 4A and C). Here, EGFR is linked to neoplasm.